2. Academic Validation
  3. Uncovering the anti-cervical cancer mechanism of Ziyuglycoside I via integrated network pharmacology molecular docking and experimental validation

Uncovering the anti-cervical cancer mechanism of Ziyuglycoside I via integrated network pharmacology molecular docking and experimental validation

  • Sci Rep. 2025 Oct 16;15(1):36258. doi: 10.1038/s41598-025-20129-z.
Shaofeng Huang # 1 2 3,  Rong Wang # 3 4 5,  Yanlun Song # 1 2 3,  Siyu Liao 2 3 4,  Minmin Ou 1 2 3,  Yuehua Huang 3 4,  Zongyun Lin 1 2 3,  Junli Wang 1 2 3,  Haimei Qin 6 7 8,  Fenglian Yang 9 10
Affiliations

Affiliations

  • 1 Reproductive Medicine Center, Affiliated Hospital of Youjiang Medical University for Nationalities, No. 18, Zhongshan Second Road, Baise, 533000, Guangxi, China.
  • 2 Graduate School, Youjiang Medical University for Nationalities, No. 98, Chengxiang Road, Baise, 533000, Guangxi, China.
  • 3 Key Laboratory of Research on Clinical Molecular Diagnosis for High Incidence Diseases in Western Guangxi of Guangxi Higher Education Institutions, No. 18, Zhongshan Second Road, Baise, 533000, Guangxi, China.
  • 4 Department of Blood Transfusion, Affiliated Hospital of Youjiang Medical University for Nationalities, No. 18, Zhongshan Second Road, Baise, 533000, Guangxi, China.
  • 5 Reproductive Medical Center, The First Affiliated Hospital of Guangxi Medical University, No. 6, Shuangyong Road, Nanning, 530000, China.
  • 6 Reproductive Medicine Center, Affiliated Hospital of Youjiang Medical University for Nationalities, No. 18, Zhongshan Second Road, Baise, 533000, Guangxi, China. haimeiqin5@163.com.
  • 7 Graduate School, Youjiang Medical University for Nationalities, No. 98, Chengxiang Road, Baise, 533000, Guangxi, China. haimeiqin5@163.com.
  • 8 Key Laboratory of Research on Clinical Molecular Diagnosis for High Incidence Diseases in Western Guangxi of Guangxi Higher Education Institutions, No. 18, Zhongshan Second Road, Baise, 533000, Guangxi, China. haimeiqin5@163.com.
  • 9 Key Laboratory of Research on Clinical Molecular Diagnosis for High Incidence Diseases in Western Guangxi of Guangxi Higher Education Institutions, No. 18, Zhongshan Second Road, Baise, 533000, Guangxi, China. 306528613@qq.com.
  • 10 School of Pharmacy, Youjiang Medical University for Nationalities, No. 98, Gengxiang Road, Baise, 533000, Guangxi, China. 306528613@qq.com.
  • # Contributed equally.
PMID: 41102283 DOI: 10.1038/s41598-025-20129-z
Abstract

We aimed to conduct a systematic analysis of the multi-target regulatory mechanisms of Ziyu glycoside I (Ziyu I) in cervical Cancer progression using network pharmacology and molecular docking techniques. Additionally, we validated our findings using cellular experiments and animal models. The PhamMapper database was used to identify drug targets for Ziyu I, while cervical cancer-related disease targets were obtained from the DisGeNET, DrugBank, GeneCards, and OMIM databases. In vitro, the effects of Ziyu I on the proliferation, migration, Apoptosis, and cell cycle were assessed using cultured HeLa and SiHa cervical Cancer cells. Network pharmacology analysis identified 68 potential targets of Ziyu I in cervical Cancer. Molecular docking findings revealed that Ziyu I had a stable binding ability to MAPK1, MAPK8, and MAPK14, which are key targets in the MAPK signaling pathway. Cellular experiments revealed that Ziyu I significantly inhibited the proliferation and migration of cervical Cancer cells and promoted Apoptosis and cell cycle arrest. Finally, a nude mice-loaded tumor assay revealed that Ziyu I had significant anti-cervical Cancer activity in vivo. Ziyu I inhibits cervical Cancer progression through a multitarget regulatory network involving MAPK signaling pathway-mediated inhibition of cell proliferation and migration, Apoptosis activation, and cell cycle arrest.

Keywords

Cervical cancer; MAPK signaling pathway; Molecular docking; Network pharmacology; Ziyuglycoside I.

Figures
Products